UnknownPhase 2

Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease

NCT01560754

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

University of Southern California

Los Angeles, California, United States

+23 additional locations

Save this trial

University of Southern CaliforniaLos Angeles, California, United States
The Parkinsons InstituteSunnyvale, California, United States
Pacific Health Research & Education InstituteHonolulu, Hawaii, United States
The University of Kansas Medical CenterKansas City, Kansas, United States
Struthers Parkinson'S CenterGolden Valley, Minnesota, United States
Feinstein Institute For Medical Research, North Shore-Lij Health SystemManhasset, New York, United States
Pennsylvania HospitalPhiladelphia, Pennsylvania, United States
Vanderbilt University Medical CenterNashville, Tennessee, United States
University of VermontBurlington, Vermont, United States
Universitatsklinikum Giessen U. Marburg GmbHStandort Marburg, Marburg, Germany
Charite Campus Virchow KlinikumBerlin, Germany
Klinikum BremerhavenBremerhaven, Germany
Universitaetsklinikum CarlGustav CarusDresden, Germany
Neurologische Klinik der, DusseldorfDüsseldorf, Germany
Neurologische Universitaetsklinik FreiburgFreiburg im Breisgau, Germany
Klinikum Hanau GmbHHanau, Germany
Universitaetsklinikum des SaarlandesHomburg/Saar, Germany
Paracelsus-Elena-Klinik KasselKassel, Germany
Universitaetsklinikum Schlewsig-HolsteinKiel, Germany
Universitaetsklinikum LeipzigLeipzig, Germany
Otto-von-Guericke-UniversitatMagdeburg, Germany
Klinikum rechts der IsarMünchen, Germany
Universitaetsklinikum TubingenTübingen, Germany
Universitaetsklinikum UlmUlm, Germany